MacroGenics expands ZYNYZ royalty deal with Sagard, secures $60M upfront
Source: SeekingAlpha
2026-05-04 08:50:25 ET
More on MacroGenics
- MacroGenics: Oncology Opportunities In Play, But Investing Feels Like A Gamble
- MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
- MacroGenics gains removal of FDA partial hold on lead program
- Incyte fails to win FDA label expansion for cancer therapy due to issues at Novo plant
- Seeking Alpha’s Quant Rating on MacroGenics
Read the full article on Seeking Alpha
For further details see:
MacroGenics expands ZYNYZ royalty deal with Sagard, secures $60M upfront
MacroGenics Inc.
NASDAQ: MGNX
MGNX Trading
2.25% G/L:
$4.325 Last:
255,268 Volume:
$4.19 Open:
MGNX Latest News
May 14, 2026 04:01:00 pm
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
May 13, 2026 04:01:00 pm
MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation
MGNX Stock Data
$110,069,846
55,034,923
1.49%
25
N/A
Biotechnology & Life Sciences
Healthcare
US
Rockville
